CEL-SCI’s Chief Scientific Officer Discusses Cancer Immunotherapy Multikine
January 25 2016 - 9:00AM
Business Wire
CEL-SCI Corporation (NYSE MKT: CVM) Chief Scientific
Officer, Eyal Talor, Ph.D., spoke to Newswise LIVE recently to
discuss the following:
- What is head and neck cancer? Can you
provide us with a short overview?
- How are cancers in the head and neck
region treated today? How difficult is the standard-of-care for
these patients?
- Should there be a new shift in how head
and neck cancer is treated?
- How does Multikine work in harnessing
the patient’s immune system against cancer?
- A quick update on the Multikine
trial.
- How will Multikine improve the lives
and clinical outcome of patients?
- Where can more information be found on
the Multikine trial?
The video is available on the Company's website
www.cel-sci.com/investor_relations.html.
A video webcast of CEL-SCI’s Chief Executive Officer, Geert
Kersten, at the NobleCon12 - Noble Financial Capital Markets’
Twelfth Annual Investor Conference from January 19, 2016 is also
available on the Company’s website
www.cel-sci.com/investor_relations.html.
About CEL-SCI Corporation
CEL-SCI is a Phase 3 immunotherapy company with platform
technologies that can potentially treat a variety of cancers and
viral diseases. We believe that one must activate the immune system
BEFORE radiation and chemotherapy, and even before surgery, to
achieve the best results in the greatest number of patients.
CEL-SCI is conducting a Phase 3 trial in 24 countries of Multikine
(Leukocyte Interleukin Injection) for the treatment of head and
neck cancer, which accounts for about 6% of cancers globally and a
$6 billion market. Over 668 patients are already enrolled in this
study. CEL-SCI is also testing Multikine with the U.S. Navy in HIV
infected patients with HPV related diseases. CEL-SCI has
development partnerships with Teva Pharmaceuticals, Orient
EuroPharma of Taiwan, Ergomed and the NIH. The Company operates its
own 75,000 sq. ft. manufacturing facility and produces Multikine
for its clinical trials. When fully built out, this facility will
have the capacity to supply about $3 billion worth of Multikine
annually. CEL-SCI is also developing its pre-clinical L.E.A.P.S.
(Ligand Epitope Antigen Presentation System) technology as a
potential vaccine for the treatment of rheumatoid arthritis.
The Company has operations in Vienna, Virginia, and in/near
Baltimore, Maryland.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160125005213/en/
CEL-SCI CorporationGavin de Windt, 703-506-9460
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Sep 2023 to Sep 2024